The Prognostic Significance of Glucose-6-Phosphate Dehydrogenase as a Biomarker in Head and Neck Squamous Cell Carcinomas Treated with Conventional Chemoradiation

Files

Authors

Kenneth H. Barker, Oakland University William Beaumont School of Medicine Medical Student
Barbara L. Pruetz, Beaumont Health
Jessica D. Arden, Beaumont Health
Thomas J. Quinn, Beaumont Health
George D. Wilson, Beaumont Health

Description

INTRODUCTION
The prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation can be predicted using p16 as a surrogate biomarker of Human Papilloma Virus (HPV) status, but a subset of patients continues to do poorly despite a positive or negative p16 status. This project attempted to identify another biomarker, glucose-6-phosphate dehydrogenase (G6PD) as a marker for prognosis in HNSCC patients. Radiation induces oxidative damage to destroy tumor cells, and G6PD is a key enzyme involved in protecting cells from oxidative damage. The goal of this project was to identify a prognostic biomarker that would aid in recognizing patients who would not respond well to chemoradiation and potentially respond better to other therapeutic measures.

Publication Date

5-2-2022

Keywords

Squamous Cell neoplasms, radiotherapy

Disciplines

Oncology | Radiation Medicine

Recommended Citation

Baker KH, Pruetz BL, Arden JD, Quinn TJ, Wilson GD. The Prognostic significance of glucose-6-phosphate dehydrogenase as a biomarker in head and neck squamous cell carcinomas treated with conventional chemoradiation. Poster presented at: Oakland University William Beaumont School of Medicine Embark Capstone Colloquium; 2022 May 2; Rochester Hills, MI.

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May 2, 2022.